Twist Bioscience Announces Closing of Upsized Public Offering of Common Stock & Full Exercise of Underwriters’ Option to Pu...
14 May 2019 - 1:55AM
Business Wire
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced the closing of its
upsized underwritten public offering of 4,312,500 shares of its
common stock at a public offering price of $21.00 per share, which
includes the exercise in full by the underwriters of their option
to purchase up to an additional 562,500 shares of common stock in
this offering. Twist estimates net proceeds from the offering to be
approximately $84.1 million, after deducting underwriting discounts
and commissions and estimated offering expenses.
J.P. Morgan Securities LLC, Cowen and Company, LLC and Evercore
Group L.L.C. acted as joint book-running managers for the offering.
Robert W. Baird & Co. Incorporated acted as lead manager.
A registration statement relating to the securities sold in this
offering was filed with the Securities and Exchange Commission and
declared effective on May 8, 2019. This offering was made solely by
means of a prospectus forming part of the effective registration
statement. Copies of the final prospectus related to the offering
may be obtained from J.P. Morgan Securities LLC, Attention:
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, or from Cowen and Company, LLC, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention:
Prospectus Department, or by telephone at (631) 274-2806, or from
Evercore Group L.L.C. c/o Equity Capital Markets, 55 East 52nd
Street, 36th Floor, New York, NY 10055, or by telephone at (888)
474-0200, or by email at ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology company that has developed a disruptive DNA synthesis
platform to industrialize the engineering of biology. The core of
the platform is a proprietary technology that pioneers a new method
of manufacturing synthetic DNA by “writing” DNA on a silicon chip.
Twist is leveraging its unique technology to manufacture a broad
range of synthetic DNA-based products, including synthetic genes,
tools for next-generation sequencing (NGS) preparation, and
antibody libraries for drug discovery and development. Twist is
also pursuing longer-term opportunities in digital data storage in
DNA and biologics drug discovery. Twist makes products for use
across many industries including healthcare, industrial chemicals,
agriculture and academic research.
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve known and unknown
risks, uncertainties, and other important factors that may cause
Twist Bioscience’s actual results, performance, or achievements to
be materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
risks and uncertainties of the ability to attract new customers and
retain and grow sales from existing customers; risks and
uncertainties of rapidly changing technologies and extensive
competition in synthetic biology could make the products Twist
Bioscience is developing obsolete or non-competitive;
uncertainties of the retention of a significant customer; risks of
third party claims alleging infringement of patents and proprietary
rights or seeking to invalidate Twist Bioscience’s patents or
proprietary rights; and the risk that Twist Bioscience’s
proprietary rights may be insufficient to protect its technologies.
For a further description of the risks and uncertainties that could
cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Quarterly Report on Form
10-Q filed with the Securities and Exchange
Commission on May 2, 2019. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and Twist Bioscience specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190513005616/en/
Twist Investor Contact:Argot PartnersMaeve
Conneighton212-600-1902maeve@argotpartners.com
Twist Media Contact:Angela Bitting925-
202-6211media@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Apr 2024 to May 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From May 2023 to May 2024